Xifaxan (大腸躁鬱症) - 2023年為止的預測與市場分析
Xifaxan (Irritable Bowel Syndrome) - Forecast and Market Analysis to 2023
|出版日期||內容資訊||英文 59 Pages
|Xifaxan (大腸躁鬱症) - 2023年為止的預測與市場分析 Xifaxan (Irritable Bowel Syndrome) - Forecast and Market Analysis to 2023|
|出版日期: 2014年12月31日||內容資訊: 英文 59 Pages||
本報告提供大腸躁鬱症 (IBS) 治療藥物──Xifaxan之相關調查，提供您疾病概要與免疫學，疾病管理，競爭情形，未滿足需求機會，開發平台評估，主要企業的資訊，今後的市場預測等資訊。
Irritable Bowel Syndrome (IBS) is a common disorder characterized by abdominal discomfort associated with altered bowel function. Although IBS is not a life-threatening disorder, it has a considerable effect on patients' quality of life (QOL). In terms of volume, the IBS market is a large, albeit naive, one, with only a small number of pharmacotherapies indicated for the treatment of the disorder, and it is also characterized by significant unmet needs.
Xifaxan (rifaximin) was developed by Alfa Wassermann, and is currently approved for the treatment of hepatic encephalopathy and traveler's diarrhea in the US and 5EU, except in France. In 1996, Salix Pharmaceuticals gained the exclusive rights to Xifaxan in the US, and is currently developing this product for the treatment of patients with IBS-D (Salix Pharmaceuticals, 2014).